Clinical trial
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
NCT07898774 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 21, 2027
- Completion date
- January 17, 2031
- Enrollment
- 30 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.
c3 glomerulopathy (c3g), primary immune-complex membranoproliferative glomerulonephritis (ic-mpgn), recurrent glomerular disease after kidney transplantation
Arms
As registered; 1 arm.
-
Pegcetacoplan
Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Occurrence of Clinically Significant Recurrent Disease
Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy
Lead sponsor's other trials
Swedish Orphan Biovitrum, most recent start first.
+76 more trials See the organization page